Group Gp Lp Column III Sells 343,717 Shares of Tenaya Therapeutics (NASDAQ:TNYA) Stock

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) major shareholder Group Gp Lp Column III sold 343,717 shares of Tenaya Therapeutics stock in a transaction dated Tuesday, February 10th. The shares were sold at an average price of $0.82, for a total transaction of $281,847.94. Following the completion of the transaction, the insider directly owned 4,253,298 shares of the company’s stock, valued at $3,487,704.36. This trade represents a 7.48% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Wednesday, February 11th, Group Gp Lp Column III sold 4,056,573 shares of Tenaya Therapeutics stock. The shares were sold at an average price of $0.68, for a total value of $2,758,469.64.

Tenaya Therapeutics Stock Up 0.6%

Shares of NASDAQ:TNYA traded up $0.00 during trading on Thursday, hitting $0.68. 4,480,550 shares of the company traded hands, compared to its average volume of 3,880,488. The business’s fifty day moving average is $0.83 and its 200-day moving average is $1.15. The stock has a market capitalization of $113.83 million, a price-to-earnings ratio of -0.88 and a beta of 3.18. Tenaya Therapeutics, Inc. has a one year low of $0.36 and a one year high of $2.35.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its earnings results on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.03. On average, analysts forecast that Tenaya Therapeutics, Inc. will post -1.35 EPS for the current year.

Institutional Trading of Tenaya Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Renaissance Technologies LLC grew its position in Tenaya Therapeutics by 10.3% in the fourth quarter. Renaissance Technologies LLC now owns 1,850,867 shares of the company’s stock worth $1,317,000 after buying an additional 172,665 shares during the last quarter. Raiffeisen Bank International AG boosted its stake in shares of Tenaya Therapeutics by 157.1% during the 4th quarter. Raiffeisen Bank International AG now owns 900,000 shares of the company’s stock worth $630,000 after acquiring an additional 550,000 shares in the last quarter. Empery Asset Management LP acquired a new position in shares of Tenaya Therapeutics in the 4th quarter worth $3,852,000. Geode Capital Management LLC grew its holdings in shares of Tenaya Therapeutics by 1.5% in the 4th quarter. Geode Capital Management LLC now owns 1,193,355 shares of the company’s stock worth $849,000 after acquiring an additional 17,820 shares during the last quarter. Finally, GSA Capital Partners LLP lifted its holdings in shares of Tenaya Therapeutics by 220.2% during the fourth quarter. GSA Capital Partners LLP now owns 1,478,612 shares of the company’s stock valued at $1,052,000 after purchasing an additional 1,016,808 shares during the last quarter. 90.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TNYA has been the subject of several analyst reports. Canaccord Genuity Group reduced their price objective on Tenaya Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Chardan Capital reduced their price target on Tenaya Therapeutics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, December 12th. Morgan Stanley set a $2.00 price target on Tenaya Therapeutics in a research note on Thursday, January 8th. HC Wainwright reduced their price objective on shares of Tenaya Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, December 12th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Wednesday, January 21st. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $4.50.

About Tenaya Therapeutics

Tenaya Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of gene therapy solutions for cardiovascular diseases. Leveraging a proprietary adeno‐associated virus (AAV) platform, the company aims to deliver durable, one‐time treatments for patients suffering from genetic cardiomyopathies and other inherited heart disorders. Its research programs center on optimizing vector design, delivery methods and manufacturing processes to enhance tissue specificity and minimize immune responses.

Founded in 2018 and headquartered in San Carlos, California, Tenaya has built a diversified pipeline of product candidates targeting conditions such as hypertrophic cardiomyopathy and other genetically driven forms of heart disease.